Article

Touchless technology could enable early detection, treatment of eye diseases that cause blindness

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

Investigators believe a non-contact laser imaging system could help doctors diagnose and treat eye diseases that cause blindness much earlier than is now possible.

The new technology,1 developed by engineering investigators at the University of Waterloo in Waterloo, Ontario, Canada, is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

With current testing methods, diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma, which have no symptoms in their early stages, are usually diagnosed only after vision is irreversibly affected.

“We are optimistic that our technology, by providing functional details of the eye such as oxygen saturation and oxygen metabolism, may be able to play a critical role in early diagnosis and management of these blinding diseases,” said Parsin Haji Reza, director of the PhotoMedicine Labs at Waterloo Univeristy, in a statement.

According to investigators, patented technology at the core of the new system is known as photoacoustic remote sensing (PARS). It uses multicolored lasers to almost instantly image human tissue without touching it.

When used for eyes, the non-invasive, non-contact approach improves both patient comfort and the accuracy of test results, according to the university.

The technology is also being applied by Haji Reza and investigators in his lab to provide microscopic analyses of breast, gastroenterological, skin and other cancerous tissues, and to enable real-time imaging to guide surgeons during the removal of brain tumors.

According to Richard Weinstein, MD, an ophthalmologist and co-founder of the Ocular Health Centre, PARS may move ophthalmology beyond the current gold standard in ophthalmological imaging.

“For the first time, not just in ophthalmology but in the entire medical field, diagnosis and treatment of disease could be made prior to structural change and functional loss,” he said in a statement.

Haji Reza, a professor of systems design engineering and co-founder of startup company illumiSonics, said researchers are working with several ophthalmologists and hope to start clinical trials within two years.

---

Reference

1. Z. Hosseinaee, N. Pellegrino, et. al; Functional and structural ophthalmic imaging using noncontact multimodal photoacoustic remote sensing microscopy and optical coherence tomography; Scientific Reports; May 2021; Accessed June 16, 2021.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
© 2025 MJH Life Sciences

All rights reserved.